Compare GDHG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDHG | IXHL |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 37.0M |
| IPO Year | 2022 | 2024 |
| Metric | GDHG | IXHL |
|---|---|---|
| Price | $1.32 | $3.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.6K | ★ 109.0K |
| Earning Date | 07-11-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.16 |
| 52 Week High | $8.69 | $6.39 |
| Indicator | GDHG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 46.08 |
| Support Level | $1.27 | $3.07 |
| Resistance Level | $1.98 | $3.68 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 13.04 | 63.04 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.